The patent claim type you file determines the commercial territory you own, not just the legal category you occupy. Biotech founders who treat this decision as a filing technicality frequently discover gaps in their IP estate at the worst possible moment: during generic entry litigation, a licensing negotiation, or an investor due diligence review. Understanding the structural difference between composition of matter and method of use claims, and when to file each, is one of the highest-leverage decisions you’ll make before your first patent application.
Key Takeaways
- A composition of matter patent protects the physical or chemical structure of a novel compound, regardless of how it is used.
- A method of use patent protects a specific application or therapeutic use of a compound, not the compound itself.
- Composition claims offer broader protection but require genuine structural novelty; method claims are narrower but remain commercially significant.
- Both claim types carry a 20-year term from filing, but their effective exclusivity windows differ depending on when each is filed.
- Filing both claim types on the same asset — claim stacking — is standard pharmaceutical IP practice and extends commercial exclusivity.
Why Claim Type Determines IP Scope
Both composition of matter and method of use claims fall under utility patents governed by 35 U.S.C. § 101, which defines patentable subject matter as any process, machine, manufacture, or composition of matter. The landmark Diamond v. Chakrabarty (1980) ruling confirmed that living organisms, and by extension novel biological compositions, qualify as patentable subject matter. That decision opened the door to modern biotech IP. The Association for Molecular Pathology v. Myriad Genetics (2013) ruling then drew the boundary: isolated naturally occurring DNA sequences are not patentable, but cDNA and novel synthetic constructs are.
The practical consequence is that your claim type selection isn’t semantic. It determines what competitors can and cannot do with your innovation. File only a method claim when a composition claim was still available, and you’ve handed a competitor the right to manufacture your compound for any use you didn’t explicitly claim.
Composition of Matter Patents: Structure-Based Protection
A composition of matter patent protects the physical or chemical makeup of a novel substance, including a new molecular entity, a biologic, a formulation, or a defined combination of two or more substances. Protection is structure-based: any product containing the claimed compound infringes the patent regardless of how it is used.
What Qualifies for a Composition Claim
In pharmaceutical development, a composition patent on a new molecular entity is the anchor asset in any IP portfolio. It blocks all uses of that compound, giving the holder the broadest possible exclusivity. The claim language typically opens with “A compound comprising…” followed by a precise structural definition. Independent claims define the broadest scope; dependent claims add specific structural variants, salt forms, or formulation parameters that narrow the claim but create fallback positions if the independent claim is challenged.
Biologics present a harder challenge. Defining the molecular structure of a monoclonal antibody or gene therapy vector with sufficient precision to satisfy USPTO examination guidelines is technically demanding. The structural complexity of biologics means composition claims are harder to obtain and defend compared to small molecule claims, which is one reason the Biologics Price Competition and Innovation Act provides 12 years of regulatory exclusivity as a parallel protection mechanism.
Limitations of Composition Claims
Composition claims face § 101 eligibility challenges when the claimed substance is too close to a naturally occurring compound. They also require genuine novelty: if your compound appears in prior art, even in a different context, the composition claim may fail. Prior art analysis before filing is non-negotiable.
Method of Use Patents: Application-Based Protection
A method of use patent protects a specific application or therapeutic use of a compound, not the compound itself. In pharmaceutical contexts, this is called a method of treatment patent. The claim is defined by what the compound does in a particular context: treating a specific disease, in a specific patient population, at a specific dose or regimen.
When Method Claims Become Your Primary Strategy
Method of use claims are the right primary strategy when the compound itself is already in the public domain but your specific therapeutic application is novel. A known molecule with a newly discovered oncology indication, for example, supports a method claim even if no composition claim is available. This is the structural logic behind many drug repurposing programs.
The claim language differs structurally from a composition claim. A method claim opens with “A method of treating [condition X] comprising administering [compound Y] to a patient in need thereof…” The specificity of the claimed method defines both the scope of protection and the ease of design-around. A competitor who administers the same compound for a different indication doesn’t infringe your method claim. That narrowness is the primary limitation you need to price into your IP strategy.
Enforceability Considerations
Method of use infringement requires demonstrating that the infringing party is practicing the specific claimed method. In pharmaceutical contexts, this often means proving that a generic manufacturer’s product label induces physicians to use the drug in the patented way, a doctrine known as induced infringement. Composition patent infringement is structurally simpler to establish because it’s product-based, not use-based.
Head-to-Head Comparison: Scope, Duration, and Strategy
| Criterion | Composition of Matter | Method of Use |
|---|---|---|
| What is protected | The compound or substance itself | A specific use or therapeutic application |
| Scope of protection | Broad — all uses of the compound | Narrow — the specific claimed use only |
| Patent term | 20 years from filing date | 20 years from filing date |
| Enforceability | Structure-based; easier to establish | Use-based; requires proving method practiced |
| Design-around risk | Lower — compound structure must be avoided | Higher — different indication avoids claim |
| EPO treatment | Broadly accepted for novel compounds | Second medical use claims accepted under EPC Art. 54(5) |
Claim Stacking: Building Layered IP Protection
Filing both composition and method of use claims on the same asset is standard practice in pharmaceutical IP strategy. A composition patent filed at discovery protects the compound across all uses. Method of use patents filed during clinical development protect specific therapeutic applications validated by trial data. The two layers overlap during the composition patent’s life and then the method claims carry exclusivity forward after composition patent expiry.
Consider a small molecule oncology program. The composition patent, filed at the time of synthesis, covers the molecular entity. As Phase II data confirms efficacy in a specific tumor type at a defined dosing regimen, you file method of use claims on that indication. If a second indication emerges in Phase III, you file again. Each method claim, filed later in the development timeline, has a later expiry date. That architecture is why some branded drugs maintain meaningful exclusivity years after generic manufacturers can legally manufacture the active compound.
Should you consult a patent attorney to evaluate whether a composition claim is still available before defaulting to a method filing? Yes, and that conversation should happen before any public disclosure, conference abstract, or preprint submission. In the US, public disclosure triggers a one-year grace period under 35 U.S.C. § 102. In most European jurisdictions, the EPO applies an absolute novelty standard: any prior disclosure eliminates the right to file, with no grace period.
Practical Decision Framework for Your Asset
The decision is direct at the extremes. A genuinely novel compound with no prior art warrants a composition claim as the primary filing. A known compound with a new therapeutic application requires a method of use claim. The complex middle ground requires careful analysis.
- Novel small molecule, no prior art: File composition claim first; add method claims as clinical indications are validated.
- Novel formulation of a known compound: Prior art analysis required; composition claim on the formulation may be available; method claims on specific therapeutic uses should follow.
- Known biologic, new patient population: Method of use claim on the specific population; check whether the dosing regimen or combination therapy supports additional claims.
- Gene therapy vector with novel structural elements: Composition claim on the vector construct; method claims on the therapeutic application.
Your IP estate should be planned before the first patent is filed, not assembled reactively. The most defensible pharmaceutical IP portfolios combine both claim types, filed at strategic intervals tied to development milestones, with continuation applications preserving the right to add claims as new data emerges. That architecture takes planning. It also takes a patent attorney with biotech prosecution experience, not just general IP counsel.
FAQ: Composition of Matter and Method of Use Patents
Can you hold both types of patents on the same drug?
Yes. Filing both claim types on the same asset is standard practice in pharmaceutical IP strategy and creates overlapping protection across the drug’s commercial lifecycle.
What happens to method of use protection after composition patent expiry?
Method of use patents filed later in development may still be in force after the composition patent expires, maintaining exclusivity on specific indications even when generics can legally manufacture the compound.
Are method of use patents valid in Europe?
Yes. The European Patent Convention Article 54(5) permits second medical use claims in the form “Compound X for use in treating condition Y,” which functions as the EPO equivalent of a US method of use claim.
How does biosimilar entry interact with these claim types?
Biosimilar manufacturers can enter the market after composition patent expiry but may still face method of use barriers if the approved therapeutic application remains under patent protection.
What’s the biggest strategic mistake founders make with these claim types?
Filing only a method of use claim when a composition claim was still available. That decision can expose the company to generic entry years earlier than necessary and significantly reduces licensing leverage.
This article provides strategic and educational context for informational purposes only and does not constitute legal advice. Biotech founders and life science entrepreneurs should consult a qualified patent attorney or registered patent agent before making any filing decisions, particularly when operating across US (USPTO) and European (EPO) jurisdictions where claim eligibility standards differ materially.
